• Health Care M&A Deals, April 2 , 2021

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week is... Read More »
  • SOC Telemed Acquires Access Physicians

    The national telehealth provider SOC Telemed has announced a new deal for Access Physicians valued at $194 million upfront with additional potential consideration based on performance. Access Physicians is an experienced multi-specialty acute inpatient telemedicine provider focused on cardiac care, inpatient hospital care, tele-neurology,... Read More »
  • Procaps Group Merges with Union Acquisition

    If you were looking for another SPAC deal this week, say no more. Procaps Group announced a reverse merger with Union Acquisition Corp. II (NASDAQ: LATN). Founded in 1977, Procaps is a leading integrated international healthcare and pharmaceutical company with a successful history of growth and diversification. Procaps is the largest... Read More »
  • Organon Hits the Ground Running

    Early in March 2020, Merck & Co., Inc. (NYSE: MRK) announced the spin-off of a new company focused on women’s health. The new company, Organon & Co., will have a portfolio of more than 60 trusted medicines that address an entire spectrum of conditions that women face. Organon is expected to have a global footprint with approximately... Read More »
  • SomaLogic Goes Public With SPAC

    They just don’t stop coming. Another private healthcare company has agreed to go public via SPAC in a $1.23 billion deal. SomaLogic is merging with CM Life Sciences II (NASDAQ: CMIIU), a special purpose acquisition company affiliated with Casdin Capital, LLC and Corvex Management LP. SomaLogic is a commercial-stage proteomics company with... Read More »
Organon Hits the Ground Running

Organon Hits the Ground Running

Early in March 2020, Merck & Co., Inc. (NYSE: MRK) announced the spin-off of a new company focused on women’s health. The new company, Organon & Co., will have a portfolio of more than 60 trusted medicines that address an entire spectrum of conditions that women face. Organon is expected to have a global footprint with approximately 10,000 employees with headquarters located in Jersey City, New Jersey. If the name rings any bell at all, it’s because Organon was originally a subsidiary of Schering-Plough Corporation, which Merck acquired in 2009 for a whopping $41 billion. Schering-Plough actually bought Organon in 2007 from Akzo Nobel (OTCMKTS: AZKOY) for $15.8 billion, according... Read More »
Hill-Rom Holdings Hits the Ground Running

Hill-Rom Holdings Hits the Ground Running

Only a month into the new year and Hill-Rom Holdings, Inc. (NYSE: HRC) already has two acquisitions on the books, according to search results in our Healthcare Deal Database. Hill-Rom Holdings operates as a medical technology company worldwide. Its products enable earlier diagnosis and treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication and shifting care closer to home.  Back on January 19, the medical device company acquired Bardy Diagnostics, Inc. for $375 million in cash, plus net operating losses valued at more than $20 million. Bardy Diagnostics was founded in 2013 and helps improve clinical management and outcomes for... Read More »
Boston Scientific Buys Preventice Solutions, Inc.

Boston Scientific Buys Preventice Solutions, Inc.

The medical device giant, Boston Scientific Corporation (NYSE: BSX), is kicking off the new year with a bang. The company has announced the acquisition of Preventice Solutions, Inc., which offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors to cardiac event monitors and mobile cardiac telemetry.  Boston Scientific is offering $925 million upfront in cash and up to an additional $300 million in a potential commercial milestone payment. Boston Scientific has been an investor in Preventice since 2015 and currently holds an equity stake of approximately 22 percent., which will result in a $720 million net payment and a net milestone... Read More »
Royal Philips Buys BioTelemetry

Royal Philips Buys BioTelemetry

The medical device giant Royal Philips (NYSE: PHG) is back with a new deal, adding BioTelemetry, Inc. (NYSE: BEAT). The deal is valued at $2.8 billion, consisting of $72.00 per share in cash, or a 16.5% premium to BEAT’s closing price on December 17, 2020. BioTelemetry, formerly known as CardioNet, is a leading provider of remote cardiac diagnostics and monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing for healthcare and clinical research customers. BioTelemetry generated an annualized 2020 revenue of $458 million and annualized 2020 EBITDA of $92.3 million. The acquisition is a strong fit with... Read More »
Boston Scientific Divests BTG Specialty Pharmaceuticals Business

Boston Scientific Divests BTG Specialty Pharmaceuticals Business

In November 2018, Boston Scientific Corporation (NYSE: BSX) purchased BTG plc for $4.8 billion, according to search results in our Healthcare Deal Database. BTG develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases. However, the company also had an acute care pharmaceutical division, which based on recent deal activity, it seemed the medical device giant wasn’t too interested in holding onto the non-medical device portions of BTG. In the fourth quarter of 2019, Boston Scientific sold the pharmaceutical licensing royalties unit of BTG, and last week, the company announced the second divestment. Boston Scientific is selling... Read More »
Royal Philips Buys BioTelemetry

Smith & Nephew Returns to the M&A Market

It’s been over a year since Smith & Nephew plc (NYSE: SNN) announced a transaction, but the medical device manufacturer is back on the acquisition trail. On September 29, the company purchased Integra LifeSciences Holdings Corporation’s (NASDAQ: IART) extremity orthopedics business for $240 million. The business includes a portfolio of devices, implants and instruments for shoulder replacement as well as reconstruction of bone in the hand, wrist and elbow, and foot and ankle. This deal will significantly strengthen Smith & Nephew’s extremities business by adding a combination of a focused sales channel, complementary shoulder replacement and upper and lower extremities... Read More »